Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

In case you missed it, this week we had news about the FDA's RPD Designation of QRX003 for Netherton Syndrome, Galderma's 2 new clinical trials of nemolizumab, Allergan Aesthetics' sPMA for SKINVIVE by Juvéderm, and more.

The Weekly Roundup: June 30-July 3

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Dermatology Times Spot Test: July 3, 2025

Robin Smith, MD, MBA, discusses the future of regenerative aesthetics and her exosome-based skin care and hair care brand, Exoceuticals.

The Future of Exoceuticals and Innovative Aesthetics, According to Robin Smith, MD, MBA 

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Delgocitinib ointment shows promise as an effective, well-tolerated treatment for atopic dermatitis on the face and neck, enhancing patient satisfaction and reducing adverse effects.

New Data Support Delgocitinib for Sensitive Skin Areas

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

We would like to acknowledge and address a serious oversight related to the below article 

“Laser Advancements Transform Skin Rejuvenation.”

 After publication, it was brought to our attention that the article contains language and structure that closely mirror a previously published, peer-reviewed article in the 

Advancements in Laser Technologies for Skin Rejuvenation: A Comprehensive Review

 by Diala Haykal, MD; Hugues Cartier, MD; David Goldberg, PhD; and Michael Gold, PhD.

While the intent of the article was to summarize current advancements in laser technologies for a clinical audience, proper attribution to the original authors and publication was regrettably omitted. We recognize and respect the original work and contributions and sincerely apologize for this oversight.

The editorial team has taken steps to review our processes to ensure this does not happen again. We are committed to maintaining the highest standards of content integrity and transparency.

-------------------------------------------------------------

Laser technologies have significantly transformed dermatology, particularly in skin rejuvenation.

 Over recent decades, lasers have evolved from basic tools into sophisticated devices that offer precise, targeted treatments with minimal invasiveness and faster recovery times. This progress has expanded the range of conditions treatable by lasers and improved their customization and safety.

 There are various types of lasers, including ablative lasers that remove outer skin layers and non-ablative fractional lasers that stimulate collagen production without damaging the skin’s surface. Fractional lasers, in particular, enhance results with minimal downtime by targeting microscopic skin areas.Understanding how different wavelengths interact with skin, the process of selective photothermolysis, and the body’s healing response is crucial for optimizing laser treatments. These advancements have made skin rejuvenation more effective and accessible.

A recent review discussed the mechanisms, advantages, and personalized applications of laser technologies for diverse skin conditions, with the goal of providing insights into the scientific advancements that have improved the safety and efficacy of these treatments.

This review analyzed articles from the past 20 years on laser skin resurfacing, using keywords like “skin rejuvenation” and “laser technology” to search databases such as PubMed, Cochrane, Scopus, and Google Scholar. It includes a wide range of research, from peer-reviewed studies and clinical trials to meta-analyses, covering various laser technologies: ablative, non-ablative, fractional, hybrid, and picosecond. The review systematically examines the evolution, mechanisms, benefits, and potential adverse events of these technologies.

Out of the 329 articles screened, researchers included 92 that met the criteria based on relevance, study design, and recent advancements in laser technology for skin rejuvenation.The data gathered was categorized into the following sections:

The review stated that fractional lasers have significantly advanced skin rejuvenation by delivering targeted energy in a pixeled pattern, which speeds up healing and reduces complications compared to traditional ablative lasers. These lasers create microthermal damage that stimulates collagen production, effectively treating various skin issues such as wrinkles, acne scars, and sun damage. Recent innovations have improved customization and precision, enhancing treatment outcomes and patient experience. Fractional lasers are praised for their minimal downtime and effectiveness in skin remodeling.

CO2 and Er:YAG lasers are well-established in skin resurfacing, according to the review, known for their effectiveness in treating photoaging, scars, and wrinkles. CO2 lasers target water molecules in the skin for deep tissue ablation and collagen remodeling, while Er:YAG lasers offer a more superficial approach with reduced recovery time. Both technologies show superior efficacy compared to other treatments and are often used in combination with other modalities to enhance results.

Non-ablative lasers (NAFL), such as Nd:YAG and pulsed-dye lasers, provide skin rejuvenation with minimal downtime by targeting deeper skin layers to stimulate collagen without damaging the surface. The review stated these lasers are effective for improving skin texture, reducing wrinkles, and treating vascular lesions, offering a gentler alternative to ablative lasers.

Hybrid fractional lasers combine ablative and non-ablative technologies in a single treatment, allowing for comprehensive skin rejuvenation with reduced downtime. Researchers found this approach addresses a range of skin concerns and is noted for its effectiveness and patient satisfaction, providing noticeable improvements with minimal discomfort.

Picosecond lasers, known for their ultra-short pulse duration, are effective for treating pigmented lesions, photodamage, and scars with minimal thermal damage. Their ability to induce precise tissue disruption through lLaser-induced optical breakdown makes them versatile and effective for various skin conditions.

Laser Technologies in Ethnic Skin Rejuvenation

Advancements in laser technologies have improved safety and effectiveness for darker skin tones by minimizing risks like hyperpigmentation. Technologies such as Nd:YAG and picosecond lasers are particularly suitable for ethnic skin, offering effective treatment with reduced side effects. Researchers noted pre- and post-treatment care is crucial for optimal results.

The review found ablative lasers have improved in safety and effectiveness, with advancements reducing adverse events and recovery times. They stated proper patient selection, calibration, and post-treatment care are essential to minimize complications. Fractional and hybrid lasers further enhance safety and efficacy, though ongoing research is needed, particularly for darker skin tones.

Researchers noted different lasers interact with skin tissues in various ways: ablative lasers remove outer layers for immediate results, non-ablative lasers create microthermal zones for deeper collagen stimulation, and fractional picosecond lasers induce minimal thermal damage while promoting skin renewal. They stated that understanding these interactions is crucial for optimizing treatment outcomes.

The review found that repeated laser treatments can enhance skin rejuvenation by cumulatively improving collagen density and skin elasticity. Long-term studies show that tailored, multi-session plans offer sustained aesthetic benefits and improved skin texture.

Researchers stated that patient satisfaction with laser treatments is generally high, attributed to visible improvements in skin texture and minimal downtime. Successful outcomes are often linked to realistic expectations, comprehensive pre-treatment consultations, and effective post-treatment care.

The review found that advancements in laser technologies have significantly enhanced skin resurfacing, providing precise and effective treatments for various skin conditions. Ablative lasers like CO2 and Er:YAG target deeper skin layers but require longer recovery and can have more side effects. NAFLs, such as Nd:YAG and fractional erbium, stimulate collagen production with minimal surface damage, offering quicker recovery and fewer side effects. Fractional lasers further improve this balance by treating the skin in a pixelated manner, reducing downtime and risks. Hybrid lasers merge the benefits of both ablative and non-ablative approaches, allowing for customized treatments with reduced side effects and faster recovery.

Researchers found the integration of laser-assisted drug delivery enhances therapeutic outcomes by creating micro-channels in the skin, improving the absorption of topical treatments. They found cooling systems have also advanced, helping to manage pain and minimize side effects, thereby increasing patient comfort and safety. However, limitations such as a focus on short-term results, variability in study designs, and underrepresentation of darker skin tones in research highlight the need for ongoing innovation and research. Overall, they found laser skin resurfacing continues to evolve, offering tailored solutions that improve treatment effectiveness and safety across diverse skin types, setting a new standard in cosmetic dermatology.

Kirkland EB, Gladstone HB, Hantash BM. What's new in skin resurfacing and rejuvenation?.

Carniol PJ, Hamilton MM, Carniol ET. Current status of fractional laser resurfacing.

2015;17(5):360-366. doi:10.1001/jamafacial.2015.0693

Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. 

2004;34(5):426-438. doi:10.1002/lsm.20048

Jih MH, Kimyai-Asadi A. Fractional photothermolysis: a review and update. 

 2008;27(1):63-71. doi:10.1016/j.sder.2008.01.002

Clementoni MT, Pedrelli V, Zaccaria G, et al. Newdevelopments for fractional Co2 resurfacing for skin rejuvenation and scar reduction. 

 2020;28(1):17-28. doi:10.1016/j.fsc.2019.09.002

Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. 

 2008;58(5):719-740. doi:10.1016/j.jaad.2008.01.003

Waibel S, Pozner J, Robb C, et al. Hybrid fractional laser: A multi-center trial on the safety and efficacy for photorejuvenation. 

Haykal D, Cartier H, Maire C, et al. Picosecond lasers in cosmetic dermatology: where are we now? An overview of types and indications. 

 2023;39(1):8. Published 2023 Dec 18. doi:10.1007/s10103-023-03945-5

Kaushik SB, Alexis AF. Nonablativefractional laser resurfacing in skin of color: evidence-based review. 

Manuskiatti W, Punyaratabandhu P, Tantrapornpong P, et al. Objective and long-term evaluation of the efficacy and safety of a 1064-nm picosecond laser with fractionated microlens array for the treatment of atrophic acne scar in Asians.

 2021;53(7):899-905. doi:10.1002/lsm.23368


Laser technologies have revolutionized dermatology, particularly in skin rejuvenation, by evolving into precise, minimally invasive tools with faster recovery times. Various laser types, including ablative, non-ablative, fractional, hybrid, and picosecond, offer tailored treatments for diverse skin conditions. Fractional lasers, in particular, enhance results with minimal downtime. Advances have improved safety and efficacy, especially for ethnic skin, by minimizing risks like hyperpigmentation. Despite progress, ongoing research is needed to address limitations such as short-term focus and underrepresentation of darker skin tones in studies.

A review found repeated laser treatments show cumulative benefits, including improved collagen density and skin elasticity over time.

Laser Advancements Transform Skin Rejuvenation

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

A poster presented at the 2025 Society of Dermatology Physician Associates Summer Dermatology Conference highlighted the effectiveness of dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) in providing sustained, long-term flare control in adult patients with moderate to severe atopic dermatitis (AD).

The analysis assessed data from the phase 3 SOLO 1/2 (NCT02277743; NCT02277769)

 and SOLO-CONTINUE extension (NCT02395133)

 trials. The investigation focused on the extent to which dupilumab can prevent flare episodes over a full year of continuous treatment. 

Unlike previous studies combining dupilumab with topical corticosteroids, the present analysis centered solely on dupilumab administered alone, without adjunct therapies, to determine its standalone efficacy and safety in maintaining disease control.

Participants in the study had already responded favorably to a 16-week initial treatment phase, receiving treatment with dupilumab 300 mg once per week or once every 2 weeks. Those who demonstrated significant improvement, defined by achieving an Investigator Global Assessment score of 0/1 (indicative of complete or almost complete clearance) or at least a 75% improvement in Eczema Area and Severity Index, were eligible for extension into the next phase of the trial.

During this phase, more than 160 adults were randomly assigned into different maintenance dose groups: 300 mg every 2 weeks, 300 mg every 4 weeks, and 300 mg every 8 weeks. The study then tracked the occurrence of flares, defined as worsening requiring treatment escalation, and analyzed the duration until the first flare event.

Approximately 80% of patients (equivalent to 8 of every 10 patients) across all dosing schedules remained well controlled, with no disease flares observed throughout the duration of the 1-year follow-up.

The duration of time from baseline to first observed flare was significantly delayed in patients treated with dupilumab, regardless of whether they received injections every 2, 4, or 8 weeks.

The safety profile was consistent with known data on dupilumab, with most adverse events being mild to moderate in nature. Serious adverse events were rare, and no treatment-related deaths occurred.

"Dupilumab monotherapy over 1 year prevented flares in 8 of 10 patients regardless of the maintenance dose regimen," wrote poster authors Simpson et al.

The findings suggest that dupilumab monotherapy is highly effective in maintaining disease control over an extended period, emphasizing its role as a sustainable long-term solution in AD management.

Simpson EL, Worm M, Bissonnette R, et al. Dupilumab monotherapy prevents flares and provides sustained control of atopic dermatitis over 1 year across various dose regimens. Poster presented at: 2025 SDPA Summer Dermatology Conference; June 25-29, 2025; Washington, DC.

Study of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis (SOLO 1). ClinicalTrials.gov. Updated November 21, 2017. Accessed June 27, 2025. 

https://clinicaltrials.gov/ct2/show/NCT02277743

Study of dupilumab (REGN668/SAR231893) monotherapy administered to adult patients with moderate-to-severe atopic dermatitis (SOLO 2). ClinicalTrials.gov. Updated June 2, 2020. Accessed June 27, 2025. 

https://clinicaltrials.gov/ct2/show/NCT02277769

A study to confirm the efficacy and safety of different dupilumab dose regimens in adults with atopic dermatitis (AD) (SOLO-CONTINUE). ClinicalTrials.gov. Updated March 11, 2020. Accessed June 27, 2025. 

https://clinicaltrials.gov/ct2/show/NCT02395133

keep up to date with the latest coverage from the conference

Dupilumab has demonstrated significant efficacy in providing sustained, long-term flare control in adult patients with moderate to severe atopic dermatitis. The analysis, derived from phase 3 SOLO 1/2 and SOLO-CONTINUE trials, focused on dupilumab monotherapy without adjunct therapies. Over a year, approximately 80% of patients experienced no disease flares, regardless of dosing frequency. The time to first flare was significantly delayed, and the safety profile was consistent with known data, with most adverse events being mild to moderate. These findings underscore dupilumab's role as a sustainable long-term solution in atopic dermatitis management.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Dupilumab Maintains Long-Term Flare Control Across Dosing Regimens in Atopic Dermatitis

 approximately 2% of people worldwide will experience hair loss due to alopecia areata in their lifetime. 

When taking this statistic into account, approximately 160 million people globally have had, currently have, or will have alopecia areata, including approximately 6.7 million in the US. 

At this moment in time, it can be approximated that 700,000 people in the US, both children and adults, currently have some form of alopecia areata.

Alopecia areata - National Alopecia Areata Foundation. NAAF. June 23, 2023. Accessed August 11, 2023. 

Alopecia areata affects approximately 2% of the global population, translating to around 160 million individuals worldwide. In the United States, about 6.7 million people have experienced or will experience this condition, with an estimated 700,000 currently affected. This autoimmune disorder impacts both children and adults, leading to varying degrees of hair loss. The data underscores the prevalence of alopecia areata and highlights the need for continued research and awareness to better understand and manage this condition.

This Hair Loss Awareness Month, test your knowledge of hair loss conditions. Click here to answer this week's poll.

POLL: What Percentage of People Worldwide Will Experience Alopecia in Their Lifetime?

In early 2025, significant changes in federal research funding policies have introduced uncertainty for the medical research community, including dermatology. These developments may impact clinical trials, translational research, and the training of future physician-scientists.

The National Institutes of Health (NIH) implemented a policy capping indirect cost reimbursements at 15%, down from previous rates that often exceeded 50%.

 Although a federal judge temporarily blocked this policy following legal challenges, many institutions have already initiated hiring freezes, reduced graduate admissions, and paused research projects.

Effective January 25, 2025, the NIH introduced a simplified peer review framework for research project grants, fellowships, and training grants.

 These changes aim to streamline the application process and promote fairness by focusing on key assessments such as candidate potential and research training plans.

Federal research funding policy changes in 2025 have introduced uncertainty for the medical research community, including dermatology. The NIH capped indirect cost reimbursements at 15%, leading to hiring freezes and paused projects. A simplified peer review framework was implemented to streamline grant applications. The NIH also ended funding for climate change and health programs, and removed funding opportunities related to diversity, equity, inclusion, and health disparities. These shifts may significantly impact clinical trials, translational research, and the training of future physician-scientists.

Tanya Dougherty, PharmD, BCPS

Articles

Latest Updated Articles